This Monday, there was a pivotal ruling from the U.S., which carries significant implications for the pharmaceutical industry and healthcare costs. 🔍 Case Summary: The court rejected a legal ...
A federal judge has dismissed legal challenges to the Medicare negotiation program brought by Bristol Myers Squibb and Johnson & Johnson, ruling that their claims of unconstitutionality are unfounded.
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...
- A US district court judge has found Bristol-Myers Squibb's patent on the use of Buspar (buspirone), used in the treatment of neurotic anxiety, to be invalid. Bristol-Myers and its Mead Johnson unit ...
Bristol Myers Squibb (NYSE: BMY) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P 500 average of 1.4%. At such a high rate ...
The United States(US) Patent Office dominates the patent filings and grants with nearly 24% filings and 23% grants. The United States(US), European Patent Office(EPO), World Intellectual Property ...
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow. Its high debt load could turn off some risk ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Johnson & Johnson saw the highest growth of 114% in patent filings and 122% in grants in January in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 114% and grants by 122%.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.